<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The following on the treatments of <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> in <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> contains commentaries on endo mucosal resection; choice between other ablative therapies; the remaining genetic abnormalities following stepwise endoscopic mucosal resection and possible recurrences; the Fotelo-Fotesi <z:chebi fb="7" ids="53228">PDT</z:chebi>; the CT TNM classification of early stages of Barrett's <z:mp ids='MP_0002038'>carcinoma</z:mp>; the indications of lymphadenectomy in intramucosal <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>; the differences in lymph node yield in transthoracic versus transhiatal dissection; video-assisted lymphadenectomy; and the importance of the length of proximal esophageal resectipon; and indications of <z:e sem="disease" ids="C0677944" disease_type="Disease or Syndrome" abbrv="">sentinel node</z:e> dissection </plain></SENT>
</text></document>